Gupta P K, Charan V D, Kumar H
Department of Transfusion-Medicine, Armed Forces Medical College, Pune-411 040.
J Assoc Physicians India. 2005 Oct;53:877-82.
Acquired thrombophilic state associated with a significant risk of thrombosis is frequently encountered in malignancy. Venous and arterial thromboembolism is a common complication and patients with cancer, also present with a hypercoagulable state, even in the absence of thrombosis. Furthermore, clotting activation may play a role in tumor progression. The pathogenesis of thrombosis in cancer is multifactorial; however, a relevant role is attributed to the tumor cell capacity to interact with and activate the host hemostatic system. Among other factors, the prothrombotic action of antitumor therapies is also important. Thrombotic events can influence the morbidity and mortality of the underlying disease. Therefore, preventing these complications in cancer patients is a clinically relevant issue. Recently, new approaches to the prevention and cure of thrombosis in cancer have been investigated, and the hypothesis that the strategies to inhibit clotting mechanism may favorably affect malignant disease is gaining increasing interest. In this article the various aspects of the complex relationship between thrombosis and cancer, from pathophysiology to therapy, are reviewed.
在恶性肿瘤中，常出现与显著血栓形成风险相关的获得性血栓形成倾向状态。静脉和动脉血栓栓塞是一种常见并发症，癌症患者即使在没有血栓形成的情况下也存在高凝状态。此外，凝血激活可能在肿瘤进展中起作用。癌症中血栓形成的发病机制是多因素的；然而，肿瘤细胞与宿主止血系统相互作用并激活该系统的能力被认为起着重要作用。除其他因素外，抗肿瘤治疗的促血栓形成作用也很重要。血栓形成事件可影响基础疾病的发病率和死亡率。因此，预防癌症患者的这些并发症是一个具有临床相关性的问题。最近，人们对癌症血栓形成的预防和治疗新方法进行了研究，抑制凝血机制的策略可能对恶性疾病产生有利影响这一假设越来越受到关注。本文综述了从病理生理学到治疗等血栓形成与癌症复杂关系的各个方面。
